ID: ALA4876736

Max Phase: Preclinical

Molecular Formula: C133H194N34O42S

Molecular Weight: 2973.28

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](O)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(N)=O)[C@@H](C)O

Standard InChI:  InChI=1S/C133H194N34O42S/c1-64(2)49-85(116(194)150-84(44-48-210-10)115(193)159-94(59-104(184)185)125(203)166-106(68(8)171)108(137)186)153-120(198)90(55-74-60-144-78-28-18-17-27-77(74)78)157-114(192)83(41-43-100(136)177)151-130(208)105(66(5)6)165-124(202)89(51-70-23-13-11-14-24-70)156-121(199)91(56-101(178)179)158-113(191)82(40-42-99(135)176)146-109(187)67(7)145-110(188)80(30-21-46-142-132(138)139)147-111(189)81(31-22-47-143-133(140)141)149-127(205)96(62-169)163-123(201)93(58-103(182)183)160-117(195)86(50-65(3)4)152-118(196)87(52-72-32-36-75(173)37-33-72)154-112(190)79(29-19-20-45-134)148-126(204)95(61-168)162-119(197)88(53-73-34-38-76(174)39-35-73)155-122(200)92(57-102(180)181)161-128(206)97(63-170)164-131(209)107(69(9)172)167-129(207)98(175)54-71-25-15-12-16-26-71/h11-18,23-28,32-39,60,64-69,79-98,105-107,144,168-175H,19-22,29-31,40-59,61-63,134H2,1-10H3,(H2,135,176)(H2,136,177)(H2,137,186)(H,145,188)(H,146,187)(H,147,189)(H,148,204)(H,149,205)(H,150,194)(H,151,208)(H,152,196)(H,153,198)(H,154,190)(H,155,200)(H,156,199)(H,157,192)(H,158,191)(H,159,193)(H,160,195)(H,161,206)(H,162,197)(H,163,201)(H,164,209)(H,165,202)(H,166,203)(H,167,207)(H,178,179)(H,180,181)(H,182,183)(H,184,185)(H4,138,139,142)(H4,140,141,143)/t67-,68+,69+,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,105-,106-,107-/m0/s1

Standard InChI Key:  ATMSTELHXVEGAU-HGUOCSJCSA-N

Associated Targets(Human)

Glucagon receptor 2563 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Gastric inhibitory polypeptide receptor 542 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glucagon-like peptide 1 receptor 111429 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Glucagon receptor 187 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Gastric inhibitory polypeptide receptor 4 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glucagon-like peptide 1 receptor 55 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 2973.28Molecular Weight (Monoisotopic): 2971.3811AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD..  (2021)  Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.,  64  (8.0): [PMID:33821647] [10.1021/acs.jmedchem.0c02069]

Source